The Administrators of the Tulane Educational Fund

Katalin Toth

Andrew V Schally

Marta Zarandi

A peptide selected from the group having the formulae: .alpha.) X-R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 -R.sup.6 -Thr-R.sup.8 -R.sup.9 -R.sup.10 -R.sup.11 -R.sup.12 -Val-Leu-R.sup.15 -Gln-Leu-Ser-R.sup.19 -R.sup.20 -R.sup.21 -Leu-Leu-Gln-Asp-Ile-R.sup.27 -R.sup.28 -R.sup.29, wherein X is H, Ac, Aqc, IAc, BrProp, For, Ibu, Nac, 2-Nac, 1- or 2-Npt, 1- or 2-Npr, PhAc, Fpr, or any other aromatic or nonpolar acyl group, R.sup.1 is Tyr, His or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, CH.sub.3 or OCH.sub.3, R.sup.2 is D-Arg, D-Cit, D-Har, D-Lys, D-Tic or D-Orn, R.sup.3 is Asp, D-Asp, Ala, D-Ala or Gly, R.sup.4 is Ala, Abu or Gly, R.sup.5 is Ile, Ala or Gly, R.sup.6 is Phe, Tic, Ala, Pro, Tpi, Nal or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, NH.sub.2, CH.sub.3 or OCH.sub.3, R.sup.8 is Asn, Gln, Ser, Thr, Val, Leu, Ile, Ala, D-Ala, D-Asn, D-Gln, D-Thr, D-Leu, Abu, D-Abu, Nle, or Alb, R.sup.9 is Ser, R.sup.10 is Tyr or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, CH.sub.3 or OCH.sub.3, R.sup.11 is Arg, D-Arg, or Cit, R.sup.12 is Lys, D-Lys, Cit, D-Cit, Orn, D-Orn, Nle or Ala, R.sup.15 is Gly, Ala, Abu or Gln, R.sup.19 is Ala or Abu, R.sup.20 is Arg, D-Arg or Cit, R.sup.21 is Lys, D-Lys, Orn or Cit, R.sup.27 is Met, Nle or Abu, R.sup.28 is Ser, Asn, Ala or Abu, R.sup.29 is Agm, Arg-NH.sub.2, Arg-OH, Cit-NH.sub.2, Cit-OH, Har-NH.sub.2 or Har-OH, and .beta.) X-A.sup.1 -B.sup.2 -A.sup.3 -R.sup.4 -R.sup.5 -R.sup.6 -Thr-A.sup.8 Ser-R.sup.10 -R.sup.11 -B.sup.12 -Val-Leu-R.sup.15 -A.sup.16 -A.sup.17 -Ser-R.sup.19 -B.sup.20 -B.sup.21 -Leu-Leu-Gln-A.sup.26 -Ile-R.sup.27 -R.sup.28 -R.sup.29, wherein a lactam bridge is formed between any one of the pairs of positions 1,2; 2,3; 8,12; 16,20; 17-21; 21,25; 25,29 or both 8,12 and 21,25 positions, and X is H, Ac, Aqc, IAc, BrProp, For, Ibu, Nac, 2-Nac, 1- or 2-Npt, 1- or 2-Npr, PhAc, Fpr, or any other aromatic or nonpolar acyl group, A is Glu, D-Glu, Gln, Asp, D-Asp, Asn, Abu, Leu, Tyr, His, Phe(Y), in which Y=H, F, cl, Br, NO.sub.2, NH.sub.2, CH.sub.3 or OCH.sub.3, Ser, Thr, Val, Ile, Ala, D-Ala, D-Asn, D-Gln, D-Thr, D-Leu, Abu, D-Abu, Nle, or Aib, B is Lys, D-Lys, Arg, D-Arg,Orn, D-Orn, or Agm; R.sup.4 is Ala, Abu or Gly, R.sup.5 is Ile, Ala or Gly, R.sup.6 is Phe, Tic, Tpi, Nal or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, NH.sub.2 CH.sub.3 or OCH.sub.3, R.sup.10 is Tyr or Phe(Y), in which Y=H, F, Cl, Br, NO.sub.2, NH.sub.2 CH.sub.3 or OCH.sub.3, R.sup.15 is Gly, Ala, Abu or Gin, R.sup.27 is Met, Nle or Abu, R.sup.28 is Ser, Asn, Asp, Ala or Abu, and pharmaceutically acceptable salts thereof.

Growing community of inventors

Metairie, LA, United States of America

Katalin Toth